{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:10:33Z","timestamp":1790345433881,"version":"4.1.0"},"reference-count":181,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Alphaviruses, flaviviruses, measles viruses and rhabdoviruses are enveloped single-stranded RNA viruses, which have been engineered for recombinant protein expression and vaccine development. Due to the presence of RNA-dependent RNA polymerase activity, subgenomic RNA can replicate close to 106 copies per cell for translation in the cytoplasm providing extreme transgene expression levels, which is why they are named self-replicating RNA viruses. Expression of surface proteins of pathogens causing infectious disease and tumor antigens provide the basis for vaccine development against infectious diseases and cancer. Self-replicating RNA viral vectors can be administered as replicon RNA at significantly lower doses than conventional mRNA, recombinant particles, or DNA plasmids. Self-replicating RNA viral vectors have been applied for vaccine development against influenza virus, HIV, hepatitis B virus, human papilloma virus, Ebola virus, etc., showing robust immune response and protection in animal models. Recently, paramyxovirus and rhabdovirus vector-based SARS-CoV-2 vaccines as well as RNA vaccines based on self-amplifying alphaviruses have been evaluated in clinical settings. Vaccines against various cancers such as brain, breast, lung, ovarian, prostate cancer and melanoma have also been developed. Clinical trials have shown good safety and target-specific immune responses. Ervebo, the VSV-based vaccine against Ebola virus disease has been approved for human use.<\/jats:p>","DOI":"10.3390\/vaccines9101187","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T23:25:15Z","timestamp":1634513115000},"page":"1187","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Self-Replicating RNA Viruses for Vaccine Development against Infectious Diseases and Cancer"],"prefix":"10.3390","volume":"9","author":[{"given":"Kenneth","family":"Lundstrom","sequence":"first","affiliation":[{"name":"PanTherapeutics, 1095 Lutry, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2021). Virus vectors for COVID-19 vaccine development. Viruses, 13.","DOI":"10.3390\/v13020317"},{"key":"ref_2","unstructured":"(2021, July 01). Regulatory Approval of COVID-19 Vaccine AstraZeneca\u2014GOV.UK, Available online: www.gov.uk."},{"key":"ref_3","unstructured":"(2021, June 10). Ad26.COV2-S FDA Approval Status. Available online: drugs.com\/history\/ad26-cov2-s.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/d41586-020-02386-2","article-title":"Russia\u2019s fast-track coronavirus vaccine draws outrage over safety","volume":"584","author":"Callaway","year":"2020","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2020). Application of viral vectors for vaccine development with a special emphasis on COVID-19. Viruses, 12.","DOI":"10.3390\/v12111324"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/mr.58.3.491-562.1994","article-title":"The alphaviruses: Gene expression, replication and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11371","DOI":"10.1073\/pnas.93.21.11371","article-title":"Alphavirus-based expression vectors: Strategies and applications","volume":"93","author":"Frolov","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1128\/JVI.77.14.7796-7803.2003","article-title":"Kunjin virus replicon vectors for human immunedefieciency virus vaccine development","volume":"77","author":"Harvey","year":"2003","journal-title":"J. Virol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-4939-6869-5_9","article-title":"Development of Recombinant Measles Virus-Based Vaccines","volume":"1581","author":"Hutzler","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_10","unstructured":"Knipe, D.M., and Howley, P.M. (2007). Rhabdoviridiae. Fields\u2019 Virology, Wolters Kluwer Health\/Lippincott Williams & Wilkins. [5th ed.]."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1038\/nbt1291-1356","article-title":"A new generation of animal cell expression vectors based on the Semliki Forest virus replicon","volume":"9","author":"Liljestrom","year":"1991","journal-title":"Biotechnology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1126\/science.2922607","article-title":"Sindbis virus: An efficient, broad host range vector for gene expression in animal cells","volume":"243","author":"Xiong","year":"1989","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0042-6822(89)90526-6","article-title":"In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: Analysis of a viable deletion mutant","volume":"171","author":"Davis","year":"1989","journal-title":"Virology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1517\/14712598.6.2.135","article-title":"Kunjin virus replicons: An RNA-based non-cytopathic viral vector system for protein production, vaccine and gene therapy applications","volume":"6","author":"Pijlman","year":"2006","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1479-0556-2-13","article-title":"Skipping the co-expression problem: The new 2A \u2018CHYSEL\u2019 technology","volume":"2","year":"2004","journal-title":"Genet. Vaccines Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1128\/JVI.72.7.5967-5977.1998","article-title":"Encapsidation of the flavivirus Kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans","volume":"72","author":"Khromykh","year":"1998","journal-title":"J. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1006\/viro.2002.1453","article-title":"Construction and characterization of subgenomic replicons of New York strain of West Nile virus","volume":"296","author":"Shi","year":"2002","journal-title":"Virology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1128\/JVI.77.2.1644-1648.2003","article-title":"Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins","volume":"77","author":"Molenkamp","year":"2003","journal-title":"J. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1128\/JVI.79.9.5414-5420.2005","article-title":"Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression","volume":"79","author":"Jones","year":"2005","journal-title":"J. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.77.16.8924-8933.2003","article-title":"Incorporation of tick-borne encephalitis virus replicons into virus-like particles by a packaging cell line","volume":"77","author":"Gherke","year":"2003","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.virusres.2008.08.015","article-title":"Bovine viral diarrhea virus is a suitable viral vector for stable expression of heterologous gene when inserted between N(pro) and C genes","volume":"138","author":"Fan","year":"2008","journal-title":"Virus Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0168-1702(02)00044-8","article-title":"Establishment and application of bicistronic classical swine fever virus genomes for foreign gene expression and complementation of E2 deletion mutants","volume":"85","author":"Stetter","year":"2002","journal-title":"Virus Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11359","DOI":"10.1073\/pnas.93.21.11359","article-title":"Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles","volume":"93","author":"Schnell","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3389\/fmicb.2011.00272","article-title":"Development and applications of VSV vectors based on cell tropism","volume":"2","author":"Tani","year":"2012","journal-title":"Front. Microbiol."},{"key":"ref_25","first-page":"513","article-title":"Vaccinia virus-free recovery of vesicular stomatitis virus","volume":"3","author":"Harty","year":"2001","journal-title":"J. Mol. Microbiol. Biotechnol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1128\/JVI.73.6.4823-4828.1999","article-title":"A recombinant measles virus expressing hepatitis B surface antigen induces humoral responses in genetically modified mice","volume":"73","author":"Singh","year":"1999","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1002\/j.1460-2075.1995.tb00266.x","article-title":"Rescue of measles viruses from cloned DNA","volume":"14","author":"Radecke","year":"1995","journal-title":"EMBO J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/nprot.2013.094","article-title":"Design and generation of recombinant rabies virus vectors","volume":"8","author":"Osakada","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/neuro.05.001.2009","article-title":"Dual transneural tracing in the rat entorhoinal-hippocampal circuit by intracerebral injection of recombinant rabies virus vectors","volume":"3","author":"Ohara","year":"2009","journal-title":"Front. Neuroanat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1348-0421.2003.tb03424.x","article-title":"Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system","volume":"47","author":"Ito","year":"2003","journal-title":"Microbiol. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2020). Self-amplifying RNA viruses as RNA vaccines. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21145130"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1016\/j.vaccine.2018.05.095","article-title":"A recombinant virus vaccine that protects both against Chikungunya and Zika virus infections","volume":"36","author":"Chattopadhyay","year":"2018","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"12077","DOI":"10.1128\/JVI.01406-14","article-title":"Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis virus","volume":"88","author":"Reed","year":"2014","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1016\/j.vaccine.2019.04.072","article-title":"Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome","volume":"37","author":"Tretyakova","year":"2019","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1016\/j.vaccine.2020.02.007","article-title":"Venezuelan equine encephalitis vaccine with rearranged genome resists reversion and protects non-human primates from viremia after aerosol challenge","volume":"38","author":"Tretyakova","year":"2020","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/infdis\/jiz202","article-title":"Immunogenicity and efficacy of a measles virus-vectored chikungunya vaccine in nonhuman primates","volume":"220","author":"Rossi","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Safronetz, D., Mire, C., Rosenke, K., Feldmann, F., Haddock, E., Geissbert, T., and Feldmann, H. (2015). A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003736"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"eaaw3163","DOI":"10.1126\/scitranslmed.aaw3163","article-title":"Vaccines inducing immunity to Lassa fever glycoprotein and nucleoprotein protect macaques after a single shot","volume":"11","author":"Mateo","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","article-title":"A recombinant Yellow Fever 17D expressing Lassa virus glycoproteins","volume":"345","author":"Bredenbeck","year":"2006","journal-title":"Virology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.vaccine.2010.11.079","article-title":"Yellow fever 17D-vectored vaccines expressing LASV GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs","volume":"29","author":"Jiang","year":"2011","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1080\/14760584.2016.1184575","article-title":"Vaccine platforms to control Lassa fever","volume":"15","author":"Lukashevich","year":"2016","journal-title":"Exp. Rev. Vaccines"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1128\/JVI.75.23.11677-11685.2001","article-title":"Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola virus","volume":"75","author":"Pushko","year":"2001","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1016\/j.vaccine.2008.05.046","article-title":"Alphavirus replicon particles acting as adjuvants promote CD8+ T cell responses to co-delivered antigen","volume":"26","author":"Thompson","year":"2008","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1016\/j.vaccine.2020.02.053","article-title":"Bivalent Junin and Machupo experimental vaccine based on alphavirus RNA replicon vector","volume":"38","author":"Johnson","year":"2020","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.1093\/infdis\/jiv019","article-title":"A Kunjin replicon virus-like vaccine provides protection against Ebola virus infection in nonhuman primates","volume":"212","author":"Pyankov","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"VSV-EBOV rapidly protects macaques against infection with the 2014\/2015 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1128\/JVI.03361-12","article-title":"Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus","volume":"87","author":"Herbert","year":"2013","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1016\/j.vaccine.2014.05.053","article-title":"A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model","volume":"32","author":"Khalil","year":"2014","journal-title":"Vaccine"},{"key":"ref_50","first-page":"1678","article-title":"The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection","volume":"12","author":"Hu","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.6.9.12739","article-title":"Development of Sanofi Pasteur tetravalent dengue vaccine","volume":"6","author":"Guy","year":"2010","journal-title":"Hum. Vaccines"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5918","DOI":"10.1016\/j.vaccine.2017.08.071","article-title":"Biodistribution and safety of a live and attenuated tetravalent dengue vaccine in the cynomolgus monkey","volume":"35","author":"Ravel","year":"2017","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/21645515.2016.1261770","article-title":"Vaccines licensed and in clinical trials for the prevention of dengue","volume":"13","author":"Torresi","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.ymthe.2018.07.010","article-title":"A nanostructured lipid carrier for delivery of a replicating viral RNA provides single, low-dose protection against Zika","volume":"26","author":"Erasmus","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Kurup, D., Wirblich, C., and Schnell, M.J. (2020). Measles-based Zika vaccine induces long-term immunity and requires NS1 antibodies to protect the female reproductive tract in the mouse model of Zika. bioRxiv.","DOI":"10.1101\/2020.09.17.301622"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"10597","DOI":"10.1128\/JVI.00923-07","article-title":"A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against virus challenge","volume":"81","author":"Devaux","year":"2007","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"10407","DOI":"10.1128\/JVI.01184-15","article-title":"Virus-like vesicle-based therapeutic vaccine vectors for chronic hepatis B virus infection","volume":"89","author":"Reynolds","year":"2015","journal-title":"J. Virol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/JVI.78.1.146-157.2004","article-title":"A single injection of recombinant measles virus vaccine expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV","volume":"78","author":"Lorin","year":"2004","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1089\/aid.1998.14.1369","article-title":"Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles","volume":"14","author":"Brand","year":"1998","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0166-0934(99)00009-9","article-title":"Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA","volume":"79","author":"Giraud","year":"1999","journal-title":"J. Virol. Methods"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.imlet.2017.08.019","article-title":"Immunogenicity of virus-like Semliki Forest virus replicon particles expressing Indian HIV-1C gag, env and pol RT genes","volume":"190","author":"Ajbani","year":"2017","journal-title":"Immunol. Lett."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Knudsen, M.L., Ljungberg, K., Tatoud, R., Weber, J., Esteban, M., and Liljestrom, P. (2015). Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0117042"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/infdis\/jiu522","article-title":"Potent immune responses in rhesus macaques induced by nonviral delivery of self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic emulsion","volume":"211","author":"Bogers","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Ito, T., Kumagai, T., Yamaji, Y., Sawada, A., and Nakayama, T. (2020). Recombinant measles AIK-C vaccine strain expressing influenza HA protein. Vaccines, 8.","DOI":"10.3390\/vaccines8020149"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1128\/JVI.03246-14","article-title":"A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine","volume":"89","author":"Ryder","year":"2015","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41541-019-0155-z","article-title":"A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades","volume":"5","author":"Furuyama","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1006\/viro.2000.0635","article-title":"Influenza virus (A\/HK\/156\/97) hemagglutinin expressed by an alphavirus replicon system protects against lethal infection with Hong Kong-origin H5N1 viruses","volume":"278","author":"Dybing","year":"2000","journal-title":"Virology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/319857","article-title":"Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus","volume":"183","author":"Fleeton","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00705-017-3578-8","article-title":"An Influenza A virus vaccine based on an M2e-modified alphavirus","volume":"163","author":"Krishnavajhala","year":"2018","journal-title":"Arch. Virol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"622385","DOI":"10.3389\/fimmu.2020.622385","article-title":"Self-amplifying pestivirus replicon RNA encoding influenza virus nucleoprotein and hemagglutinin promote humoral and cellular immune responses in pigs","volume":"11","author":"Ruggli","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1128\/JVI.01805-10","article-title":"Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus","volume":"85","author":"Sheahan","year":"2011","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.antiviral.2017.12.007","article-title":"A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization","volume":"150","author":"Liu","year":"2018","journal-title":"Antiviral Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"32657","DOI":"10.1073\/pnas.2014468117","article-title":"A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine","volume":"117","author":"Auste","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","unstructured":"(2021, June 30). Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine (COVID-19-101), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04497298."},{"key":"ref_76","unstructured":"(2021, June 30). Merck Discontinues Development of SARS-CoV-2\/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic Candidates. Available online: www.merck.com\/news\/merck-discontinues-development-of-sars-cov-2-covid-19-vaccine-candidates-continues-development-of-two-investigational-therapeutic-candidates\/."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.chom.2020.07.018","article-title":"Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice","volume":"28","author":"Case","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_78","unstructured":"(2021, June 30). Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04569786."},{"key":"ref_79","unstructured":"(2021, June 30). Merck and IAVI Discontinue Development of COVID-19 Vaccine Candidate V590. Available online: www.iavi.org\/newsresources\/press-releases\/2021\/merck-and-iavi-discontinue-development-of-covid-19-vaccine-candidate-v590."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1038\/s41467-020-20228-7","article-title":"A single dose of recombinant VSV-\u2206G-spike provides protection against SARS-CoV-2 challenge","volume":"11","author":"Tamir","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_81","unstructured":"(2021, June 30). Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04608305."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1016\/j.vaccine.2021.04.017","article-title":"Ethics and execution of developing a 2nd wave COVID vaccine\u2013Our interim phase I\/II VSV-SARS-CoV2 vaccine experience","volume":"39","author":"Levin","year":"2021","journal-title":"Vaccine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"113842","DOI":"10.1016\/j.jviromet.2020.113842","article-title":"Attenuated porcine-derived type 2 bovine viral diarrhea virus as vector stably expressing viral gene","volume":"279","author":"Tao","year":"2020","journal-title":"J. Virol. Methods"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1038\/s41467-020-17409-9","article-title":"Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibodies in mice","volume":"11","author":"McKay","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"(2021, June 30). Clinical Trial to Assess the Safety of a Coronavirus Vaccine in Healthy Men and Women. Available online: https:\/\/doi.org\/10.1186\/ISRCTN17072692.","DOI":"10.1186\/ISRCTN17072692"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.ymthe.2021.04.001","article-title":"A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice","volume":"29","author":"Gan","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Scaglione, A., Opp, S., Hurtado, A., Lin, Z., Pampeno, C., Noval, M.G., Thannickal, S.A., Stappleford, K.A., and Meruelo, D. (2021). Combination of a Sindbis-SARS-CoV-2 spike vaccine and \u03b1OX40 antibody elicits protective immunity against SARS-CoV-2 induced disease and potentiates long-term SARS-CoV-2-specific humoral and T-cell immunity. bioRxiv.","DOI":"10.1101\/2021.05.28.446009"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1128\/CVI.00173-09","article-title":"Recombinant Sindbis virus vectors designed to express protective antigen of Bacillus anthracis protect animals from anthrax and display synergy with ciprofloxacin","volume":"16","author":"Thomas","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.imbio.2008.11.016","article-title":"Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB\/c mice","volume":"214","author":"Cabrera","year":"2009","journal-title":"Immunobiology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1365-3083.2001.00951.x","article-title":"Comparative immunization study using RNA and DNA constructs encoding a part of the Plasmodium falciparum antigen Pf332","volume":"54","author":"Andersson","year":"2001","journal-title":"Scand. J. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6907","DOI":"10.1128\/JVI.72.8.6907-6910.1998","article-title":"Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice","volume":"72","author":"Tsuji","year":"1998","journal-title":"J. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"101749","DOI":"10.1016\/j.mcp.2021.101749","article-title":"Quantitative evaluation of PpSP15-LmSTI1 fusion gene expression following transfection with an alphavirus-derived self-amplifying mRNA and conventional DNA vaccine platforms","volume":"59","author":"Savar","year":"2021","journal-title":"Mol. Cell. Probes"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3855\/jidc.2171","article-title":"Outbreak of Chikungunya in the Republic of Congo and the global picture","volume":"5","author":"Kelvin","year":"2011","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/01459740.2012.679981","article-title":"The 2005\u20132007 Chikungunya epidemic in Reunion: Ambiguous etiologies, memories, and meaning-making","volume":"32","author":"Jansen","year":"2013","journal-title":"Med. Anthropol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(96)02275-1","article-title":"Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group","volume":"348","author":"Weaver","year":"1996","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measlesvirus-based chikungunya vaccine: A randomised, double-blind, placebo controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: A double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2019","journal-title":"Lancet"},{"key":"ref_98","unstructured":"(2021, June 24). A Trial to Evaluate the Optimal Dose of MV-LASV, Available online: https:\/\/clinicaltriasl.gov\/ct2\/show\/NCT4055454."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Longini","year":"2015","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Camacho","year":"2017","journal-title":"Lancet"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Maxmen, A. (2017). Ebola vaccine approved for use in ongoing outbreak. Nature.","DOI":"10.1038\/nature.2017.22024"},{"key":"ref_102","unstructured":"(2021, June 25). Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02996890."},{"key":"ref_103","unstructured":"(2021, June 25). Safety and Immunogenicity of a Novel Vaccine Formulation, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04033068."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1128\/CVI.00258-12","article-title":"Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults","volume":"19","author":"Wecker","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S287","DOI":"10.1093\/infdis\/jiy280","article-title":"Ebola virus transmission caused by persistently infected survivors of the 2014\u20132016 outbreak in West Africa","volume":"218","author":"Subissi","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Castanha, P.M.S., and Marques, E.T.A. (2020). A glimmer of hope: Recent updates and future challenges in Zika vaccine development. Viruses, 12.","DOI":"10.3390\/v12121371"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Mellado","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1080\/21645515.2016.1276125","article-title":"Research progress of therapeutic vaccines for treating chronic hepatitis B","volume":"13","author":"Li","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1080\/21645515.2019.1651141","article-title":"Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: A phase 1b placebo-controlled trial","volume":"16","author":"Zoulim","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.ymthe.2019.08.007","article-title":"Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles","volume":"27","author":"Melo","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-021-01480-7","article-title":"BNT162b2 mRNA COVID-19 vaccine: First approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.15585\/mmwr.mm695152e1","article-title":"The advisory committee on immunization practices\u2019 interim recommendation for use of moderna COVID-19 vaccine\u2013United States, December 2020","volume":"69","author":"Oliver","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nbt917","article-title":"Systemic tumor targeting and killing by Sindbis viral vectors","volume":"22","author":"Tseng","year":"2004","journal-title":"Nat. Biotechnol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/fmb.12.4","article-title":"Oncolytic Newcastle disease virus for cancer therapy: Old challenges and new directions","volume":"7","author":"Zamarin","year":"2012","journal-title":"Future Microbiol."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Aref, S., Bailey, K., and Fielding, A. (2016). Measles to the rescue: A review of oncolytic measles virus. Viruses, 8.","DOI":"10.3390\/v8100294"},{"key":"ref_117","first-page":"3605","article-title":"Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats","volume":"63","author":"Ebert","year":"2003","journal-title":"Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1038\/s41388-021-01869-4","article-title":"Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC","volume":"40","author":"Zhang","year":"2021","journal-title":"Oncogene"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/sj.cgt.7700367","article-title":"Induction of therapeutic antitumor anti-angiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus","volume":"8","author":"Yamanaka","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3171\/jns.2003.99.4.0746","article-title":"Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12","volume":"99","author":"Yamanaka","year":"2003","journal-title":"J. Neurosurg."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1089\/dna.2005.24.317","article-title":"Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18","volume":"24","author":"Yamanaka","year":"2005","journal-title":"DNA Cell. Biol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.virol.2018.06.018","article-title":"Chikungunya-vesicular stomatitis chimeric virus targets and eliminates brain tumors","volume":"522","author":"Zhang","year":"2018","journal-title":"Virology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/gt.2012.62","article-title":"Oncolytic measles virus strains have a significant antitumor activity against glioma stem cells","volume":"2","author":"Allen","year":"2013","journal-title":"Gene Ther."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Heikkil\u00e4, J.E., V\u00e4h\u00e4-Koskela, M.J., Ruotsalainen, J.J., Martikainen, M.W., Stanford, M.M., McCart, J.A., Bell, J.C., and Hinkkanen, A.E. (2010). Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0008603"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"10637","DOI":"10.1128\/JVI.01868-15","article-title":"MicroRNA attenuated clone of virulent Semliki Forest virus overcomes antiviral type I interferon in resistant mouse CT-2A glioma","volume":"89","author":"Martikainen","year":"2015","journal-title":"J. Virol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"R580","DOI":"10.1186\/bcr1199","article-title":"Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2\/neu+ metastatic breast cancer in mice","volume":"7","author":"Wang","year":"2005","journal-title":"Breast Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.cgt.7700300","article-title":"DNA vaccination against neu reduces breast cancer incidence and metastasis in mice","volume":"8","author":"Lachman","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Kramer, M.G., Masner, M., Casales, E., Moreno, M., Smerdou, C., and Chabalgoity, J.A. (2015). Neoadjuvant administration of Semliki Forest virus expressing interleukin-12 combined with attenuated Salmonella eradicates breast cancer metastasis and achieves long-term survival in immunocompetent mice. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1618-x"},{"key":"ref_129","unstructured":"(2021, July 02). A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients with Breast Cancer, Available online: ClinicalTrials.govNCT03632941."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/gt.2012.44","article-title":"Measles virus selectively blind to signaling lymphocyte activation molecule as a novel oncolytic virus for breast cancer treatment","volume":"20","author":"Sugiyama","year":"2013","journal-title":"Gene Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1016\/j.vaccine.2009.01.061","article-title":"Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma","volume":"27","author":"Cantarella","year":"2009","journal-title":"Vaccine"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1016\/j.vaccine.2016.07.051","article-title":"Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine","volume":"34","author":"Gupta","year":"2016","journal-title":"Vaccine"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"5749","DOI":"10.1128\/JVI.02835-06","article-title":"Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus","volume":"81","author":"Brandsma","year":"2007","journal-title":"J. Virol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1128\/CVI.00343-07","article-title":"Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein","volume":"15","author":"Liao","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_135","first-page":"7861","article-title":"Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA","volume":"61","author":"Velders","year":"2001","journal-title":"Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0264-410X(02)00558-3","article-title":"Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7","volume":"21","author":"Daemen","year":"2003","journal-title":"Vaccine"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"e1487913","DOI":"10.1080\/2162402X.2018.1487913","article-title":"Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens","volume":"7","author":"Ljungberg","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/gt.2008.169","article-title":"A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy","volume":"16","author":"Smeenk","year":"2009","journal-title":"Gene Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/sj.gt.3302889","article-title":"Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice","volume":"14","author":"Lyons","year":"2007","journal-title":"Gene Ther."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/10548","article-title":"Cancer therapy using a self-replicating RNA vaccine","volume":"5","author":"Ying","year":"1999","journal-title":"Nat. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1089\/hum.2012.205","article-title":"Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine","volume":"24","author":"Grossardt","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/sj.gt.3301263","article-title":"Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles","volume":"7","author":"Murphy","year":"2000","journal-title":"Gene Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/ijc.23646","article-title":"Replication competent Semliki Forest virus prolongs survival in experimental lung cancer","volume":"123","author":"Ketola","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/mt.2013.215","article-title":"Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity","volume":"22","author":"Granot","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3892\/or.2012.2109","article-title":"Live attenuated measles virus vaccine induces apoptosis and promotes tumor regression in lung cancer","volume":"29","author":"Zhao","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"387362","DOI":"10.1155\/2013\/387362","article-title":"Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas","volume":"2013","author":"Boisgerault","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/JTO.0000000000000214","article-title":"Measles vaccine strains for virotherapy of non-small cell lung carcinoma","volume":"9","author":"Patel","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"33165","DOI":"10.18632\/oncotarget.5320","article-title":"Vesicular stomatitis virus expressing interferon-\u03b2 is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer","volume":"6","author":"Patel","year":"2015","journal-title":"Oncotarget"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"9197","DOI":"10.1128\/JVI.74.19.9197-9205.2000","article-title":"Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine solid tumors and pulmonary metastases","volume":"74","author":"McAllister","year":"2000","journal-title":"J. Virol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Avogadri, F., Merghoub, T., Maughan, M.F., Hirschhorn-Cymerman, D., Morris, J., and Ritter, E. (2010). Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0012670"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1158\/2326-6066.CIR-13-0220","article-title":"Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: Therapeutic activity in the B16 melanoma mouse model and immune correlates","volume":"2","author":"Avogadri","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbrc.2015.08.003","article-title":"Synergistic antitumor efficacy of combined DNA vaccines targeting tumor cells and angiogenesis","volume":"465","author":"Yin","year":"2015","journal-title":"Biochem. Biophys. Res. Comm."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Ammour, Y., Ryabaya, O., Shchetinina, Y., Prokofeva, E., Gavrilova, M., Khochenkov, D., Vorobyev, D., Faizuloev, E., Shohin, I., and Zverev, V.V. (2020). The susceptibility of human melanoma cells to infection with the Leningrad-16 vaccine strain of measles virus. Viruses, 12.","DOI":"10.3390\/v12020173"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Kimpel, J., Urbiola, C., Koske, I., Tober, R., Banki, Z., and Wollmann, G. (2018). The Oncolytic virus VSV-GP is effective against malignant melanoma. Viruses, 10.","DOI":"10.3390\/v10030108"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"16021","DOI":"10.1038\/mto.2016.21","article-title":"Application of interferon modulators to overcome partial resistance to ovarian cancers to VSV-GP oncolytic viral therapy","volume":"3","author":"Dold","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1158\/1078-0432.CCR-06-0992","article-title":"The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer","volume":"12","author":"Hasegawa","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1158\/1078-0432.CCR-05-1803","article-title":"Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter","volume":"12","author":"Hasegawa","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/cgt.2012.33","article-title":"The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vector and irinotecan","volume":"19","author":"Granot","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/mt.2009.318","article-title":"Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy","volume":"18","author":"Zhang","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1128\/JVI.05640-11","article-title":"Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma","volume":"86","author":"Murphy","year":"2012","journal-title":"J. Virol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"10283","DOI":"10.1128\/JVI.01412-13","article-title":"Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-nulll pancreatic ductal adenocarcinoma","volume":"87","author":"Hastle","year":"2013","journal-title":"J. Virol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/cas.13064","article-title":"Measles virus selectively blind to signaling lymphocyte activity molecule has oncolytic efficacy against nectin-4 expressing pancreatic cells","volume":"107","author":"Awano","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/pros.20857","article-title":"Engineered measles virus as a novel oncolytic therapy against prostate cancer","volume":"69","author":"Msaouel","year":"2009","journal-title":"Prostate"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/07357907.2018.1434539","article-title":"Combination of vaccine-strain measles and mumps viruses enhances oncolytic activity against human solid malignancies","volume":"7","author":"Son","year":"2018","journal-title":"Cancer Investig."},{"key":"ref_165","first-page":"1204","article-title":"Evaluation of vesicular stomatitis virus mutant as an oncolytic agent against prostate cancer","volume":"7","author":"Zhao","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/ijc.31556","article-title":"Oncolytic activity of the rhabdovirus VSV-GP against prostate cancer","volume":"143","author":"Urbiola","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1158\/1078-0432.CCR-06-2202","article-title":"A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses","volume":"13","author":"Durso","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/0008-5472.CAN-06-2996","article-title":"In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: A candidate antigen for treating prostate cancer","volume":"67","author":"Gray","year":"2007","journal-title":"Cancer Res."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1158\/0008-5472.CAN-07-0445","article-title":"Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity","volume":"68","author":"Gray","year":"2008","journal-title":"Cancer Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-18-3102","article-title":"Vaccine-induced memory CD8(+) T cells provide clinical benefit in HER2 expressing breast cancer: A mouse to human translational study","volume":"25","author":"Crosby","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ymthe.2020.11.002","article-title":"First-in-human phase I clinical trial of an SFVBased RNA replicon cancer vaccine against HPV-induced cancers","volume":"29","author":"Komdeur","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e001662","DOI":"10.1136\/jitc-2020-001662","article-title":"Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ration","volume":"8","author":"Crosby","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Galanis","year":"2010","journal-title":"Cancer Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1172\/JCI42672","article-title":"An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer","volume":"120","author":"Morse","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Reiss, C. (2016). Neurotropic alphaviruses. Neurotropic Viral Infections, Springer.","DOI":"10.1007\/978-3-319-33133-1"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/cgt.2012.37","article-title":"Semliki Forest virus biodistribution in tumor-free and 4T1 mammary tumor-bearing mice: A comparison of transgene delivery by recombinant virus particles and naked RNA replicon","volume":"19","author":"Vasilevska","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"ref_177","unstructured":"(2021, July 02). FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus (Press release). U.S. Food and Drug Administration (FDA). 8 June 2006. Archived from the Original on 19 October 2009, Available online: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2006\/ucm108666.htm."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Hromic-Jahjefendic, A., and Lundstrom, K. (2020). Viral vector-based melanoma gene therapy. Biomedicines, 8.","DOI":"10.3390\/biomedicines8030060"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.vaccine.2012.11.096","article-title":"A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer","volume":"31","author":"Slovin","year":"2013","journal-title":"Vaccine"},{"key":"ref_180","first-page":"916","article-title":"Semliki Forest virus expression system: Production of conditionally infectious recombinant particles","volume":"11","author":"Berglund","year":"1993","journal-title":"Biotechnology"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1128\/JVI.73.2.1092-1098.1999","article-title":"Two-helper system for production of recombinant Semliki Forest virus particles","volume":"73","author":"Smerdou","year":"1999","journal-title":"J. Virol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/10\/1187\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:15:24Z","timestamp":1760166924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/10\/1187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":181,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["vaccines9101187"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9101187","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]}}}